Aalstad, Linn T.
Hardie, Jon A.
Espehaug, Birgitte
Thorsen, Einar
Bakke, Per S.
Eagan, Tomas M. L.
Frisk, Bente
Article History
Received: 13 July 2018
Accepted: 20 November 2018
First Online: 6 December 2018
Ethics approval and consent to participate
: Participation in the study was voluntary. Both oral and written information was given, and written consent was obtained prior to inclusion. The study was approved by the Western Norway Regional Research Ethics Committee (REK 165.08).
: Not applicable.
: PSB has received speakers’ fees from AstraZeneca, Boehringer Ingelheim, Pfizer unrelated to the current work, and received advisory board fees from Mundipharma, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline unrelated to the current work the last 36 months. TMLE reports speakers’ fees from AstraZeneca and Boehringer Ingelheim unrelated to the current work, within the last 36 months. All other authors declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.